Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPOWER-QoL: Discontinuing Premedication for Paclitaxel in Breast Cancer
NCT07478315Not yet recruiting
- Sponsor
- Hôpital Charles-LeMoyne
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of dexamethasone, diphenhydramine, cetirizine and famotidine in Hypersensitivity reaction (2 arms), sponsored by Hôpital Charles-LeMoyne. Primary endpoint: Difference in quality of life based on the EORTC QLQ-C30 v3.0 questionnaire at 9 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
dexamethasonediphenhydraminecetirizinefamotidine
03
Conditions
Hypersensitivity reaction
Beyond the preview
Go deeper on NCT07478315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478315.